Financings in Brief: Cortecs International
This article was originally published in The Gray Sheet
Executive Summary
Cortecs International: Raises [pound]46 mil. (roughly $70.6 mil.) in a private placement of 12.5 mil. "ordinary" shares to "institutions in the U.K., Europe, Japan, and the Far East." Shares in the placement "rank pari passu in all respects with the existing ordinary shares with respect to both capital and dividends," Cortecs says. The London-based firm, which recently received 510(k) clearance from FDA for its Helisal point-of-care Helicobacter pylori test, says funds from the offering "will be primarily applied to bringing forward and developing" its oral drug delivery products, several of which are in clinical trials...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.